South Africa's PIC draws fire for opposing CFR-Adcock deal; With Mexican stake buy, Richter eyes emerging markets growth;

@FiercePharma: South Africa's top business daily accuses its state pension fund of protectionism vs. a $1.2B deal with Chile's CFR Pharma. More from Reuters | Follow @FiercePharma

@EricPFierce: AstraZeneca gets former Amylin plant & Bristol-Myers Ohio plant in breakup of diabetes venture. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: As GSK hails its FDA nod for Anoro, a Novartis Advair knockoff prepares for its close-up. Story | Follow @CarlyHFierce

> South Africa's top business newspaper lambasted the state-owned Public Investment Corp. for trying to block Chile-based CFR Pharmaceuticals' buyout of the local drugmaker Adcock Ingram. Report

> Hungary-based drugmaker Richter is beefing up in emerging markets again with the $10 million purchase of a 70% stake in Mexico's DNA Pharmaceuticals. Report

> Novartis' ($NVS) generics unit Sandoz launched a Phase III trial for its biosimilar version of AbbVie's ($ABBV) megablockbuster anti-inflammatory drug Humira. Release

> Taking Gilead Sciences' ($GILD) Truvada pill to prevent HIV infection may not encourage high-risk patients to engage in risky sex, a new study found. Release | Report

> Scientists are finding a molecular basis for a potential link between GlaxoSmithKline's ($GSK) pandemic flu vaccine and the sleep disorder narcolepsy. Report

> U.S.-based Perrigo ($PRGO) has wrapped up its buyout of the Irish drug developer Elan. Report

Medical Device News

@FierceMedDev: Investors propel St. Jude Medical to new heights over 2013 rebound. Article | Follow @FierceMedDev

@MarkHFierce: So, how many device companies will go for FDA/CMS parallel review now that the pilot program has been extended? More | Follow @MarkHFierce

@MichaelGFierce: Synapse collects state-funded $2.4M for next-gen diaphragm pacing device. Item | Follow @MichaelGFierce

@GalenMoore: ICYMI: Despite tax hike, Medtronic's money still flies to Puerto Rico. Story | Follow @GalenMoore

> Decision Diagnostics is raising cash to keep its J&J glucose strip patent fight running. More

Biotech News

@FierceBiotech: Alimera, pSivida skyrocket as they give the thrice-rejected Iluvien another go. More | Follow @FierceBiotech

@JohnCFierce: Another day, another positive PhIII study for AMG 145 (PCSK9). Release | Follow @JohnCFierce

@DamianFierce: GSK and Theravance score another FDA approval with Anoro, a novel COPD combo therapy. News | Follow @DamianFierce

@EmilyMFierce: BRAIN Initiative announces 6 funding opportunities for biomedical researchers. More from FierceBiotech Research | Follow @EmilyMFierce

> Alimera, pSivida skyrocket as they give the thrice-rejected Iluvien another go. Article

> Vertex's Kalydeco flunks a Phase III for cystic fibrosis. Story

> AstraZeneca will pay up to $4.1B for Bristol's share of their diabetes pact. More

> Bayer bags Algeta's cancer drug portfolio for $2.9B. News

Pharma Manufacturing News

> Hacked off: Congress members, PhRMA urge an outside audit of the FDA data breach. Story

> Regeneron will invest $300M, hire 300 in its revamp of a Dell plant in Ireland. More

> The FDA and EU members will share some inspection duties. News

> AstraZeneca will take over 2 U.S. plants in its $4.1B diabetes drug transfer. Report

> CEO Nakayama says Daiichi Sankyo is helping Ranbaxy deal with the FDA's concerns. Article

> FDA puts veterinary drugs from banned Wockhardt plants on a leash. Item

Vaccines News

> Schulman leaves Pfizer weeks before start date of new top vaccine job. More

> CDC: Vaccines prevented 6M cases of flu, 79,000 hospitalizations last year. News

> Moderate alcohol consumption acts as vaccine adjuvant in monkeys. Article

> Physician failings raise doubts about the potency of U.K. vaccines. Story

> Agenus stock jumps on Phase II brain cancer vaccine data. Piece

> California calls for unapproved Bexsero to stop its meningitis outbreak. Item

And Finally... About half of the raw chicken breasts in a U.S. sampling carried antibiotic-resistant "superbug" bacteria. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.